Pulse Biosciences (NASDAQ:PLSE) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Pulse Biosciences (NASDAQ:PLSE) from a sell rating to a hold rating in a report published on Saturday.

A number of other brokerages have also commented on PLSE. Needham & Company LLC started coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They set a “buy” rating and a $58.00 price target for the company. Mizuho set a $45.00 price objective on shares of Pulse Biosciences in a research note on Monday, August 10th. Canaccord Genuity Group lifted their price objective on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a report on Monday, August 10th. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

Pulse Biosciences Stock Performance

Shares of Pulse Biosciences stock opened at $47.57 on Friday. Pulse Biosciences has a 52 week low of $12.56 and a 52 week high of $50.90. The stock has a 50 day moving average price of $35.38 and a two-hundred day moving average price of $27.00. The stock has a market capitalization of $3.29 billion, a PE ratio of -40.31 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The firm had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Research analysts forecast that Pulse Biosciences will post -1.29 EPS for the current year.

Insider Activity

In other Pulse Biosciences news, COO Liane Rae Teplitsky purchased 1,036 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was bought at an average cost of $48.23 per share, with a total value of $49,966.28. Following the completion of the transaction, the chief operating officer owned 1,036 shares of the company’s stock, valued at $49,966.28. The trade was a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 74.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Pulse Biosciences during the 2nd quarter valued at $40,672,000. Bank of America Corp DE purchased a new position in shares of Pulse Biosciences in the 2nd quarter worth about $40,115,000. California State Teachers Retirement System boosted its holdings in shares of Pulse Biosciences by 2,600.0% in the 2nd quarter. California State Teachers Retirement System now owns 567,883 shares of the company’s stock worth $15,747,000 after buying an additional 546,850 shares during the last quarter. Portolan Capital Management LLC bought a new position in Pulse Biosciences during the third quarter valued at about $1,809,000. Finally, Brooklyn Investment Group grew its position in Pulse Biosciences by 330.7% during the fourth quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock valued at $1,844,000 after buying an additional 100,081 shares during the period. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.